Xencor, Inc. (XNCR) – What Are Researchers Thinking About This Stock?

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have received a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $44.00.

A number of research firms recently issued reports on XNCR. Raymond James Financial boosted their target price on shares of Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 1st. Wedbush increased their price target on shares of Xencor from $30.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 27th. Wells Fargo & Company increased their price target on shares of Xencor from $30.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 27th. Wall Street Zen upgraded shares of Xencor from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, Truist Financial boosted their price objective on shares of Xencor from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th.

Get Our Latest Analysis on XNCR

Insiders Place Their Bets

In related news, Director Richard Ranieri sold 81,252 shares of Xencor stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $39.25, for a total value of $3,189,141.00. Following the transaction, the director owned 18,514 shares in the company, valued at approximately $726,674.50. This trade represents a 81.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.08% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of large investors have recently modified their holdings of XNCR. Steward Partners Investment Advisory LLC acquired a new position in shares of Xencor in the 3rd quarter valued at about $25,000. Integrated Wealth Concepts LLC acquired a new stake in Xencor during the 2nd quarter worth approximately $30,000. Bessemer Group Inc. increased its position in Xencor by 18.7% during the 3rd quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 282 shares in the last quarter. Allworth Financial LP acquired a new stake in Xencor during the 2nd quarter worth approximately $55,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Xencor in the third quarter valued at approximately $95,000.

Xencor Price Performance

XNCR opened at $33.40 on Friday. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -21.00 and a beta of 0.78. The business has a 50-day moving average of $28.27 and a two-hundred day moving average of $18.65. Xencor has a 12 month low of $10.38 and a 12 month high of $40.60.

Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.83. The company had revenue of $116.52 million during the quarter, compared to the consensus estimate of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The company’s quarterly revenue was up 453.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) EPS. Equities research analysts anticipate that Xencor will post -2.61 earnings per share for the current year.

Xencor Company Profile

(Get Free Report)

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.

Featured Stories

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.